Combination Therapy with Relugolix in the Treatment of Advanced Prostate Cancer

The National Comprehensive Cancer Network®, Pfizer Global Medical Grants (Pfizer) and Myovant Sciences (Myovant) are collaborating to offer a new grant opportunity seeking proposals for investigator-initiated research with relugolix. Pfizer and Myovant Sciences (hereafter, “Grantor”) is providing $5 million in funding to support clinical research studies to further evaluate the effectiveness of relugolix in combination with other therapies for the treatment of advanced prostate cancer. The Grantor will serve as the funding organization. Grants are available to all investigators from institutions within the United States.